Episode
Episode 477: A Boatload of Data on Omega-3 Benefits
- Published
- Jan 20, 2026
- Duration seconds
- 1711
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/heart-doc-vip-with-dr-joel-kahn-327754/episodes/episode-477-a-boatload-of-data-on-omega-3-benefits/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/heart-doc-vip-with-dr-joel-kahn-327754/episode-477-a-boatload-of-data-on-omega-3-benefits.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
This week, Dr. Kahn dives into four new research papers on omega-3 fatty acids and their impact on heart and brain health. The discussion highlights several eye-opening findings, including reduced atrial fibrillation risk and improved cardiovascular outcomes in patients undergoing hemodialysis. Dr. Kahn also explains how omega-3 intake supports brain health and why the "right" dose depends on the specific condition being addressed. Food sources, fish oil, algae-based supplements, and ahiflower are compared as practical ways to reach optimal omega-3 levels. Additional topics in this episode include newly approved AI software for early detection of heart disease, the role of statins in patients with type 2 diabetes, the science—and hype—around NAD+ boosters, and emerging data on Prolon fasting for Crohn's disease. Dr. Kahn also reviews concerning research on heart rhythm risks associated with high-intensity endurance exercise in athletes over the age of 50. As always, the episode blends cutting-edge research with real-world clinical insight to help clarify what actually matters for long-term heart health. Thanks to The Fresh Pressed Olive Oil Club — get a bottle for $1 at getfreshDRKAHN.com . More About This Episode This episode takes a deeper look at why omega-3 blood levels matter more than simply taking a supplement. Dr. Kahn reviews large population studies linking higher omega-3 levels to lower risks of atrial fibrillation, early-onset dementia, and major cardiovascular events, including in high-risk groups such as patients on hemodialysis. The key takeaway: testing omega-3 status and personalizing intake may be far more effective than a one-size-fits-all approach. Beyond omega-3s, Dr. Kahn explores several timely and surprising topics, including AI-enhanced CT scan…